Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $151,164.75 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Alfred Ford, Jr. sold 6,275 shares of the company’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $24.09, for a total transaction of $151,164.75. Following the completion of the sale, the insider directly owned 99,564 shares of the company’s stock, valued at $2,398,496.76. The trade was a 5.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Trading Up 4.5%

NASDAQ:KMTS opened at $26.40 on Friday. Kestra Medical Technologies, Ltd. has a 52 week low of $14.30 and a 52 week high of $30.00. The firm has a 50-day moving average price of $22.96 and a two-hundred day moving average price of $22.57. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. The firm has a market cap of $1.55 billion, a price-to-earnings ratio of -10.91 and a beta of 0.58.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). The business had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. On average, equities analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current fiscal year.

Institutional Trading of Kestra Medical Technologies

A number of large investors have recently bought and sold shares of KMTS. Farther Finance Advisors LLC bought a new stake in shares of Kestra Medical Technologies in the fourth quarter valued at $31,000. Russell Investments Group Ltd. lifted its position in shares of Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after buying an additional 474 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after acquiring an additional 1,638 shares during the period. Daiwa Securities Group Inc. bought a new position in shares of Kestra Medical Technologies during the 4th quarter worth $72,000. Finally, Brown Brothers Harriman & Co. increased its holdings in Kestra Medical Technologies by 26.8% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after acquiring an additional 656 shares during the last quarter.

Analyst Ratings Changes

KMTS has been the topic of several research analyst reports. BTIG Research boosted their price objective on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Weiss Ratings cut Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 16th. Oppenheimer initiated coverage on shares of Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating on the stock. Wall Street Zen upgraded shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $27.83.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.